Business Context and Reporting Period
This Form 8-K covers events occurring on May 12, 2026, and a corporate update issued on May 13, 2026, by Allogene Therapeutics, Inc. The filing primarily addresses the termination of a strategic partnership and the announcement of financial results for the quarter ended March 31, 2026.
Key Financial Metrics and Agreements
- Termination of License Agreement: Allogene terminated an Exclusive License Agreement with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. regarding allogeneic CAR T cell therapies (targets: BCMA, CD70, FLT3, DLL3) in Greater China, Taiwan, South Korea, and Singapore.
- Historical Consideration: Under the terminated agreement, Allogene previously received a $40.0 million upfront payment and $79.0 million in non-cash consideration (Overland preferred stock).
- Termination Terms: No termination payments were made. Allogene surrendered a portion of its equity in Overland for no consideration, retaining approximately 3% of Overland's outstanding equity on a fully diluted basis.
- Financial Results: The filing references a press release (Exhibit 99.1) containing Q1 2026 results. Specific revenue, profit, cash flow, or liquidity figures are not provided in the text of this 8-K.
Material Changes
- Partnership Restructuring: The exclusive license for four specific targets in the Asia-Pacific region has been terminated in its entirety.
- Equity Position: Allogene's ownership stake in Overland Therapeutics was reduced to approximately 3% following the surrender of equity interests.
- Governance: A Second Amended and Restated Shareholders' Agreement was executed to reflect the new equity ownership and governance rights.
Outlook, Risks, and Management Commentary
- Future Filings: The full Termination Agreement and Shareholders' Agreement will be filed as exhibits to the Form 10-Q for the quarter ending June 30, 2026.
- Legal Status: The parties provided a mutual release of claims arising under the License Agreement through the effective date.
- Missing Data: The filing text does not provide specific guidance, updated financial outlook, or detailed risk factors beyond the termination of the agreement. Detailed financial metrics for Q1 2026 are contained in the referenced press release but are not present in this document.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q1 2026 revenue, cash burn, and liquidity figures.
- Verify the exact terms of the equity surrender and the remaining 3% stake in Overland Therapeutics.
- Monitor the upcoming Form 10-Q (due for the quarter ending June 30, 2026) for the full text of the Termination and Shareholders' Agreements.
- Assess the impact of losing the exclusive license for BCMA, CD70, FLT3, and DLL3 targets in the Greater China, Taiwan, South Korea, and Singapore territories on future royalty potential.